http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
OptimumLogin
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
OptimumLogin2024-07-02 08:31:512024-07-02 09:48:47Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2024-03-21 08:30:042024-03-20 12:58:46Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2024-03-14 07:54:302024-03-14 07:53:43Mission Therapeutics raises £25.2 million to progress clinical candidates in the area of mitophagy
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-12-14 08:30:322023-12-14 15:26:48Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-12-05 08:44:502023-12-05 08:47:07Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325 for the treatment of Parkinson’s Disease
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
0
0
KellySouthern
http://missiontherapeutics.com/wp-content/uploads/2017/04/mission-therapeutics-web-1.png
KellySouthern2023-11-13 10:00:182023-11-10 17:58:27Mission Therapeutics announces publication in Nature Communications outlining potential of experimental drug MTX325 as a disease-modifying therapy for Parkinson’s Disease
Scroll to top
